Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record.

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions

Open access
Tak, Won Young, Lin, Shi-Ming, Wang, Yijun, Zheng, Jiasheng, Vecchione, Aldo, Park, Soo Young, Chen, Min Hua, Wong, Stephen, Xu, Ruocai, Peng, Cheng-Yuan, Chiou, Yi-You, Huang, Guan-Tarn, Cai, Jianqiang, Abdullah, Basri Johan Jeet, Lee, June Sung, Lee, Jae Young, Choi, Jong-Young, Gopez-Cervantes, Julieta, Sherman, Morris, Finn, Richard S., Omata, Masao, O'Neal, Michael, Makris, Lukas, Borys, Nicholas, Poon, Ronnie, Lencioni, Riccardo·2018·Clinical Cancer Research

Abstract

Purpose: Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of doxorubicin contained within a heat-sensitive liposome. When heated to ≥40°C, LTLD locally releases a high concentration of doxorubicin. We aimed to determine whether adding LTLD improves the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) lesions with a maximum diameter (dmax) of 3 to 7 cm. Experimental Design: The HEAT Study was a randomized, double-blind, dummy-controlled trial of RFA ± LTLD. The 701 enrolled patients had to have ≤4 unresectable HCC lesions, at least one of which had a dmax of 3 to 7 cm. The primary endpoint was progression-free survival (PFS) and a key secondary endpoint was overall survival (OS). Post hoc subset analyses investigated whether RFA duration was associated with efficacy. Results: The primary endpoint was not met; in intention-to-treat analysis, the PFS HR of RFA + LTLD versus RFA alone was 0.96 [95% confidence interval (CI), 0.79-1.18; P = 0.71], and the OS HR ratio was 0.95 (95% CI, 0.76–1.20; P = 0.67). Among 285 patients with a solitary HCC lesion who received ≥45 minutes RFA dwell time, the OS HR was 0.63 (95% CI, 0.41–0.96; P < 0.05) in favor of combination therapy. RFA + LTLD had reversible myelosuppression similar to free doxorubicin. Conclusions: Adding LTLD to RFA was safe but did not increase PFS or OS in the overall study population. However, consistent with LTLD's heat-based mechanism of action, subgroup analysis suggested that RFA + LTLD efficacy is improved when RFA dwell time for a solitary lesion ≥45 minutes. Clin Cancer Res; 24(1); 73–83. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2433

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 167

Metadata

Authors
Tak, W. Y., Lin, S.-M., Wang, Y., Zheng, J., Vecchione, A., Park, S. Y., Chen, M. H., Wong, S., Xu, R., Peng, C.-Y., Chiou, Y.-Y., Huang, G.-T., Cai, J., Abdullah, B. J. J., Lee, J. S., Lee, J. Y., Choi, J.-Y., Gopez-Cervantes, J., Sherman, M., Finn, R. S., Omata, M., O'Neal, M., Makris, L., Borys, N., Poon, R., & Lencioni, R.
Venue
Clinical Cancer Research
Published
2018-01-01
Volume
24
Issue
1
Pages
73-83
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2762066258
Cited by
167
References
0
FWCI
8.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2433
The paper
Tak, W. Y., Lin, S.-M., Wang, Y., Zheng, J., Vecchione, A., Park, S. Y., Chen, M. H., Wong, S., Xu, R., Peng, C.-Y., Chiou, Y.-Y., Huang, G.-T., Cai, J., Abdullah, B. J. J., Lee, J. S., Lee, J. Y., Choi, J.-Y., Gopez-Cervantes, J., Sherman, M., . . . Lencioni, R. (2018). Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.